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ABSTRACT 
Through the delivery of large international projects including ICGC and TCGA, knowledge 
of cancer genomics is reaching saturation point. Enabling this to improve patient outcomes 
now requires embedding comprehensive genomic profiling into routine oncology practice. 
                                                          
1 *Equal contribution 
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Towards this goal, this study defined the biologically and clinically relevant genomic 
features of adult cancer through detailed curation and analysis of large genomic datasets, 
accumulated literature and biomarker-driven therapeutics in clinic and development. The 
characteristics and prevalence of these features were then interrogated in 2,348 whole 
genome sequences, covering 21 solid tumour types, generated by the PCAWG project. 
This analysis highlights the predominant contribution of copy number alterations and 
identifies a critical role for disruptive structural variants in the inactivation of clinically 
important tumour suppressor genes, including PTEN and RB1, which are not currently 
captured by diagnostic assays. This study defines a set of essential genomic features for 
the characterisation of common adult cancers. 
Keywords: genonics;  cancer;  molecular profiling 
1.  INTRODUCTION 
Over the past decade, substantial knowledge has accumulated around the genomic 
aberrations that underpin the development and progression of cancer, through the 
concerted efforts of large worldwide collaborations including the International Cancer 
Genome Consortium (ICGC), The Cancer Genome Atlas (TCGA) and, most recently, the 
Pan-Cancer Analysis of Whole Genomes (PCAWG) (Lawrence 2014; Bailey 2018; PCAWG 
2020). As a consequence, the discovery of common/phenotypically strong cancer genes, 
which contribute the majority of driver events, is now close to saturation. Indeed, in a recent 
analysis of 2,658 whole genomes, only around 5% of cases did not have their genomic 
driver(s) identified (PCAWG 2020). Our current level of knowledge, therefore, is sufficient to 
define the vast majority of the clinically and biologically relevant cancer genomic space with 
a high degree of certainty. 
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Whilst this lexicon of cancer variants is close to completion, genomic profiling has yet to 
deliver on its potential for improving outcomes for cancer patients (Prasad 2016). Advances 
to date have largely been based on a single gene - single drug paradigm delivered through 
a limited genomic test (a ‘companion diagnostic’), as exemplified by EGFR inhibitor therapy 
for EGFR-mutant lung cancers. While this model achieves dramatic responses for some 
patients, there is growing appreciation that a different approach is required to unlock the full 
potential of precision medicine, in order to help a wider range of cancer patients and to 
prevent the often rapid acquisition of resistance to targeted therapies (Biankin 2015). 
Precision oncology requires an integrated analysis of the full complement of genomic 
events that underpin malignant transformation, disease progression and therapeutic 
response. Achieving this in the real world requires an assay that is able to deliver high-
quality information from available biopsy material, requiring tolerance for small samples, 
formalin-exposed DNA and low tumour cellularity (Roy-Chowdhuri 2015, Silk 2018). In 
addition, this information needs to be deliverable at scale, at a cost and using infrastructure 
that is achievable within publicly funded healthcare systems. These technical specifications 
are not yet met by whole genome sequencing (WGS) and hence WGS has been 
commissioned for only 3% of cancer cases in England following completion of the 100,000 
genomes project (www.england.nhs.uk/publication/national-genomic-test-directories/). 
Whole exome sequencing (WES) is often viewed as the second choice when WGS is not 
possible. However, WES is not a good option for cancer profiling; firstly, because the vast 
majority of genes are not cancer genes and therefore most of the sequencing data 
generated from WES has no clinical utility, and secondly, because cancers contain driver 
events out with the coding exome, including alterations in regulatory regions (Wang 2012, 
Huang 2013) and fusion gene junctions, that may be missed by WES assays. Targeted 
capture sequencing technology is able to deliver all classes of genomic variant, and 
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deployment of this approach will ensure the majority of cancer patients benefit quickly from 
the genomic knowledge delivered by ICGC, TCGA and PCAWG.  
A current critical bottleneck in the translation of accumulated genomic knowledge into 
improved outcomes for patients is the accurate definition of content for targeted cancer 
assays, such that the maximum amount of genomic information is delivered for the 
maximum number of patients. To address this challenge, we performed an objective and 
exhaustive curation of published studies and databases to define the genomic features that 
drive neoplastic transformation, disease course, and therapeutic response and resistance. 
The prevalence in cancers and the type of genomic events affecting these features were 
then characterised in detail using 2,348 cancer whole genome sequences from the PCAWG 
dataset. These data inform the design of cancer assays able to deliver the vast majority of 
clinically and biologically relevant genomic information at low cost from real-world samples. 
2. RESULTS 
2.1 Comparison of existing assays 
A range of sequencing-based cancer diagnostics are currently available from commercial 
and healthcare providers. These assays commonly report information for 400-500 genes. 
While this is broadly consistent with estimates of the total number of genes that play a 
biological role in cancer (i.e. the total number of cancer genes) (Stratton 2009, 
Martincorena 2018, PCAWG 2020), analysis of the overlap in content between eight high-
profile providers reveals poor correlation, with less than 15% of genes included in all tests, 
and over half of the genes present in only 1 or 2 assays (Figure 1). Technical performance 
aside, this finding highlights significant variability in the quantity and quality of clinically 
meaningful genomic data that is generated by existing cancer assays.  
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2.2 Defining assay content: gene level alterations 
A list of 2,002 candidate cancer genes was generated by combining the outputs of large 
statistical driver gene studies (Lawrence 2014, Martincorena 2018, PCAWG 2020) with 
genes included in commercial and healthcare assays (Figure 1 and AACR-GENIE v5.0). 
The statistical studies are probabilistic in nature and include a false discovery rate (FDR) 
which is generally set at 5-10%. As a consequence, aggregating outputs from these models 
leads to an accumulation of false positives (which are different between studies), while 
intersecting outputs from multiple studies identifies true positives as those that are identified 
as cancer genes by independent studies. Consistent with this, of the 1,474 potential cancer 
genes identified by the 8 studies of small variant drivers (Supplementary Table 1), only 
2.2% of genes were identified by all 8 approaches, and 48.5% of genes were only identified 
by a single study (Supplementary Figure 1). 
The 2,002 genes were scored and filtered based on their occurrence in nineteen studies 
(Supplementary Table 1) using mutation, hotspot, copy number and fusion scores (Figure 
2). This approach yielded a set of 447 high-confidence cancer genes. In order to future-
proof this gene set, it was augmented with knowledge of biomarkers with potential utility 
from emerging clinical trial data and/or strong pre-clinical rationale for a role in cancer. 
Particular attention was paid to genomic markers of response and resistance to treatment, 
including immunotherapy (Keenan 2019), as genomic alterations resulting in therapy 
resistance may reside outside of known cancer genes, and could, therefore, be missed by 
the curation of cancer gene studies. A small number of genes (n=12) that passed the 
filtering but lacked biological plausibility were excluded, including receptors for low-density 
lipoprotein and thyroid stimulating hormone. Some low prevalence cancer types are under-
represented in large statistical cohorts and additional genes for these were included 
through curation of the literature. From the total set of starting genes, 149 genes (43 of 
Jo
ur
na
l P
re
-p
ro
of
Journal Pre-proof
 
Real-world cancer assay design           Page 6 of 18 
 
which passed screening) were found to be altered only in haematological malignancy; these 
genes were segregated for inclusion in a separate haemato-oncology assay. The final 
output of this process yielded 555 genes directly implicated in the genesis or evolution of 
solid adult tumours.  
The 555 solid cancer driver genes identified by this process were then assigned to three 
tiers based on their current utility in clinical practice and drug development. The first tier, 
termed cancer CORE, includes genes that have an actual role or immediate potential as 
clinically relevant biomarkers through informing therapy (resistance/response) or prognosis, 
including emerging biomarkers being tested in clinical trials, particularly novel mechanisms 
of response and resistance to immunotherapy, or where strong pre-clinical evidence exists. 
The next tier, cancer PLUS, comprises high confidence cancer genes without current 
clinical utility, along with potential markers of therapeutic response/resistance for which 
mechanisms are yet to be fully characterised. The final tier, cancer MAX, comprises 
probable cancer genes and markers of therapeutic response/resistance for which current 
data are more speculative (Figure 2, Supplementary Table 2). 
 
2.3 Analysis of existing assays 
The tiered list of solid cancer driver genes was mapped back onto the clinical cancer 
assays analysed in the Figure 1. This analysis, shown in Figure 3, demonstrated that 
clinically important CORE genes were reasonably (but not entirely) represented across the 
available assays. Notably, many of the assays include a significant proportion of genes for 
which objective evidence for a role in cancer was not found. 
 
2.4 Prevalence of gene-level variant types 
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Currently available cancer diagnostics have mostly been designed for the detection of small 
variants (base substitutions and small insertions/deletions). This strategy biases towards 
the comprehensive characterisation of oncogenes, which are predominantly activated by 
point mutations, at the expense of tumour suppressor genes, which can be inactivated by 
mutation, whole or partial gene or exon deletion, or disruptive structural variants (e.g. 
translocations) within their coding or non-coding footprint. Additional genomic events of 
relevance include copy number gains and structural variants resulting in fusion genes. 
To determine the scope and characteristics of biologically relevant driver genomic 
alterations targeting the cancer CORE set of genes, we interrogated the PCAWG cohort of 
high-quality cancer genomes. This cohort of 2,348 participants, with unique whole genome 
cancer sequences representing common solid tumour types, has been analysed by the 
ICGC PCAWG Consortium to generate a consensus set of genomic aberrations, 
encompassing all known variant types (PCAWG 2020). As a pre-requisite, oncogene 
versus tumour suppressor gene (TSG) status was assigned for each gene to facilitate 
classification of driver versus passenger events. Assignment of TSG versus oncogene 
status was based on knowledge of both biological function (in normal and malignant states, 
as well as in therapeutic resistance), and patterns of recurrent mutations observed in 
cancer. In addition, a third category is required (termed TO) to account for genes that show 
tumour suppressor or oncogene activity in different tissue contexts, and for genes where 
different functional states (gain or loss of function) are implicated in oncogenesis and 
therapeutic response/resistance (for example, JAK family genes where activating mutations 
drive malignant transformation and loss of function mutations impart resistance to 
immunotherapy) (Supplementary Figure 2).  
Small variants were classed as driver events if they were recurrent in a large data set 
(AACR-GENIE v5.0) or if they resulted in disruption of genes classified as TSG or TO (see 
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Methods for full details). Gene-level amplification was classified according to consensus 
criteria for genomic analyses (≥5 copies in a diploid cancer or ≥9 copies in a tetraploid 
cancer; Van Loo 2010, Stephens 2012). For a subset of oncogenes, a clear link exists 
between amplification and a role in cancer, including receptor tyrosine kinases and cell 
cycle components such as cyclin family genes (Supplementary Table 3). For other 
oncogenes, assigning driver status to copy number gains is not so straightforward, as the 
biological consequences of amplification are unclear, for example intracellular signalling 
pathway intermediaries. For these genes, amplification was only annotated as a driver 
event when amplification was observed in conjunction with a small variant driver. For gene 
deletion and disruptive structural variants, driver status was only assigned in the presence 
of biallelic genomic aberrations (i.e. homozygous deletion, or heterozygous deletion + 
structural variant and so forth). For fusion events, structural variants targeting a subset of 
oncogenes in the CORE set known to be fusion partners were screened for potential gene 
fusions and other activating structural variants; rearrangements were considered as drivers 
if the variant resulted in a known activating event or intersected a reported fusion partner of 
the oncogene. 
Integration of cancer CORE driver events in the PCAWG cohort provided an overview of 
how different variant classes contribute to biologically and clinically relevant events across 
cancer types (Figure 4). This analysis highlighted the critical contribution of structural and 
copy number alterations and verifies previous studies that have identified cancers such as 
colorectal as largely small variant driven, in contrast to rearrangement-driven tumours such 
as ovarian cancer and sarcoma (Ciriello 2013).  
Figure 4 highlights the important contribution of disruptive structural variants to cancer 
biology. To further investigate this under-appreciated class of variant, the contribution of 
different variant types was examined in important tumour suppressor genes (Figure 5). This 
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demonstrated that the contribution of structural variants to TSG inactivation is highly 
variable, with inactivation of a subset of TSGs being frequently due to this variant class. 
Genes commonly inactivated by disruptive structural variants include CD58 (55%), NF1 
(32%), RB1 (28%) and PTEN (21%). The contribution of structural variants to inactivation of 
each TSG is also highly variable between tumour types (Figure 6). 
Disruptive structural variants are not detected by the majority of diagnostics currently in 
clinical use. Failure to detect such events has the potential to adversely impact both clinical 
decision-making and therapeutic development. Among the tumour suppressor genes 
commonly targeted by disruptive structural variants, there are a number that are important 
in current therapeutic development. Loss of PTEN function is associated with 
hyperactivation of PI3K signalling which can be targeted by small molecule inhibitors, with 
clinical trials currently underway in prostate cancer (Hanker 2019). Importantly, 27% of 
PTEN loss in prostate cancer involves a disruptive structural variant (Figure 6), which would 
not be detected by currently available diagnostics. Failure to identify the full complement of 
relevant genomic events risks either depriving patients of a potentially useful therapy or 
yielding a false-negative clinical trial outcome due to inaccurate patient selection. Another 
example of a gene commonly inactivated by structural variants is RB1, an important 
biomarker of resistance to CDK4/6 inhibitors such as palbociclib, with this class of event 
contributing to 47% and 43% of RB1 inactivation in breast and ovarian cancer respectively 
(Figure 6). Together, these findings underscore the importance of the defining and 
capturing the full range of genomic events that alter the activity of known cancer 
biomarkers. 
 
3. DISCUSSION 
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Equitable access to genomic testing requires a tumour-type agnostic platform that is both 
compatible with real-world delivery and maximises the amount of useful genomic 
information generated. This study provides a pathway to the development of such assays, 
by defining the extent of the biologically and clinically relevant genomic space, and by 
characterising the classes and prevalence of genomic events that report this information. A 
key finding is the necessity to look beyond small coding variants in order to capture 
clinically useful information (Figure 7), with disruptive structural variants highlighted as a 
clinically impactful variant class that is not currently reported by the majority of available 
assays. 
The cancer CORE feature set defines the current clinical biomarker space, covering 
approved therapy, clinical trials and strong pre-clinical biomarkers, along with markers of 
prognosis and treatment response/resistance including immunotherapy for adult solid 
tumours. Targeted capture sequencing provides a technology platform to deliver the vast 
majority of this information using routinely processed clinical biopsy samples from common 
adult tumours. The PLUS and the MAX feature sets can be deployed for hypothesis-driven 
biomarker discovery and agnostic discovery respectively in therapeutic development.  
Genes that are specific to haematological cancers were excluded from the gene list, which 
is intended to be used for the to development of assays for common adult solid tumours. It 
is important to note, however, that the list of haematology-specific genes identified by this 
study is unlikely to represent the entirety of the genes implicated in haematological 
malignancy, as the datasets used in this study are relatively underpowered for the detection 
of haemato-oncology driver genes. The completion of a haemato-oncology assay would 
require analysis and curation of additional specific datasets to ensure comprehensive 
coverage. 
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Whilst gene-level variants have traditionally been the major focus of cancer research, 
genome-level alterations provide additional clinically and biologically relevant information. 
Independent studies have highlighted the potential prognostic impact of the degree of 
genomic disorganisation within a tumour (Sansregret 2016), and microsatellite instability 
and tumour mutational burden have recently risen to prominence in the context of predicting 
response to immunotherapy (Keenan 2019). Additional predictors of response to 
immunotherapy that lie outside of the coding genome include the presence of viral DNA and 
the activity of endogenous retrotransposons (Smith 2018, Kim 2018).  
A well-designed cancer assay is able to capture the vast majority of clinically relevant 
genomic information through targeted capture and sequencing of DNA, including gene level 
information as well as the genome-level alterations outlined above. For genes harbouring 
coding region drivers, targeting of all coding exons, including essential splice sites, is 
optimal for tumour suppressor genes and preferable for oncogenes. For tumour suppressor 
genes that are inactivated by structural variants (Figure 5), targeting of the whole gene 
footprint is required in order to capture these events. For genes targeted by copy number 
alterations, assay design should include enough targeted regions to ensure good 
resolution. This is particularly important for small genes such as B2M and BCL2 which may 
require additional regional intronic tiling in order to provide sufficient copy number 
resolution. For genes that are only targeted by copy number alteration and not by small 
variants, tiling of the entire coding region may not be necessary. The inclusion of a 
genome-wide copy number backbone can improve the quality of both gene and 
chromosome level copy number calling. The capture of gene fusions at the DNA level can 
be limited if the size of the genomic region in which the breakpoints cluster is large. 
Fortunately, the majority of the clinically important fusions found in common adult solid 
tumours can be captured at the DNA level, with tiling focused on the introns where the 
Jo
ur
na
l P
re
-p
ro
of
Journal Pre-proof
 
Real-world cancer assay design           Page 12 of 18 
 
fusion breakpoints fall. Regarding tumour mutational burden, current evidence suggests 
that a genomic footprint of 1-1.5 Mb is sufficient for accurate estimation. Additional genomic 
features that may be considered include regions of microsatellite instability, 
retrotransposons and genotyping SNPs (to ensure sample integrity). 
The content and design of individual cancer assays brings together considerations including 
target cancer type(s), the classes of variants to be detected and the overall size (and thus 
reagent costs) of the assay. Pan-cancer mutation prevalence for the driver genes identified 
in this study is shown in Supplementary Table 2, complemented by breakdown by tumour 
type and by variant class in Supplementary Tables 4 and 5 respectively. Together, this 
information can be used to prioritise genes for inclusion, and to ensure that assays are 
designed to capture all relevant classes of genomic variant. Example overviews of potential 
assay designs are shown in Supplementary Table 6.  
The Cancer CORE feature list can be converted into a targeted capture assay with a 
genomic footprint of approximately 1.8 Mb. This includes full footprint tiling of 12 clinically 
important tumour suppressor genes and capture of 12 gene fusions, along with genome-
wide copy number, microsatellite instability, tumour mutational burden and retrotransposon 
activity. The reagent costs for this type of design (covering targeted capture library 
preparation and Illumina sequencing) are in the region of €200 per sample. As such, this 
represents an affordable assay that is able to deliver the vast majority of clinically relevant 
information for common adult solid tumours. 
Together, this analysis provides a roadmap to unlock the utility of aggregated genomic 
knowledge, through the delivery of comprehensive genomic profiling for all cancer patients 
as part of routine clinical care. 
4. METHODS 
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High-confidence cancer genes were defined according to objective criteria using data 
garnered from a comprehensive review of published analyses and genomic datasets 
(Supplementary Table 1). For each gene, objective evidence supporting a role for somatic 
alteration in cancer was compiled by intersecting independent data sources, including 
studies based on mathematical models, to identify genes enriched for protein-altering 
mutations (‘driver genes’), genes harbouring recurrently mutated ‘hotspot’ codons, regions 
of recurrent copy number loss or gain, and recurrent gene fusion events (see 
Supplementary Methods for full details). The approach is predicated on the notion that each 
individual approach to driver gene identification will generate both true positive and false 
positive results. True positive results with be replicated by different studies using either 
different methodologies or different underlying datasets. False positive results, however, 
are likely to be dataset and/or analytical method dependent, and are unlikely to be 
reproduced by different studies. Thus driver events identified by orthogonal approaches will 
be enriched for true driver genes. The variant types resulting in oncogenic alterations in the 
subset of these genes with current clinical utility were then characterised across 2,348 
unique whole genome sequences from solid tumours from the ICGC Pan-Cancer Analysis 
of Whole Genomes cohort (PCAWG 2020), for which analysis of all classes of genomic 
alteration is available. 
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Figure 1. Comparison of cancer NGS assay gene content from commercial and healthcare 
providers. Piechart displays the intersect of genes across 8 cancer NGS diagnostics (table; 
total n=1,084 genes), showing that less than 15% of genes are covered by all 8 assays, 
with over half the genes targeted found on only 1 or 2 panels. 
Figure 2. Cancer gene selection decision tree. Schematic of the process used to identify 
high-confidence cancer driver genes. The pie chart shows the assessment and tiering of 
2,002 genes present on commercial or LDT-delivered cancer panels 
Figure 3. Comparison of cancer NGS assay gene content from commercial and healthcare 
providers with an objectively defined and clinically tiered set of cancer driver genes. 
Figure 4. Contribution of different genomic variant types to the important driver events 
underpinning different cancer types. Analysis of the cancer CORE set of relevant genes. 
Note: due to the diverse targets, not all of which are covered in this analysis, the 
contribution of fusions will be under-estimated in the sarcoma profile; no FGFR fusions 
were detected in the biliary tract samples which is likely due to the lower prevalence of 
these alterations in East Asia (cohort origin: Singapore). SV: disruptive structural variant; 
mutation: single nucleotide variants and indels; NET: neuroendocrine tumour. Cancer type 
[number of samples]: colorectal [52], thyroid [48], endometrial [44], bladder [23], melanoma 
[107], NSCLC [84], hepatocellular [336], head & neck [56], cervical [20], biliary tract [12], 
gastric [68], pancreatic adeno [232], CNS [287], oesophageal [97], breast [211], renal [186], 
pancreatic-NET [81], ovarian [110], prostate [199], bone [61], sarcoma [34]. 
Figure 5. Contribution of different genomic variant combinations to the inactivation of key 
tumour suppressor genes. Cancer CORE genes containing 10 or more driver variants 
across the PCAWG cohort. SV: disruptive structural variant; mutation: single nucleotide 
variants and indels 
Figure 6. Contribution of different variant classes to genomic events resulting in disruption 
of PTEN and RB1 tumour suppressor genes. Cancer types with 5 or more driver variants in 
the relevant gene are shown. SV: disruptive structural variant; mutation: single nucleotide 
variants and indels; NET: neuroendocrine tumour. 
Figure 7. Pan-cancer distribution of cancer relevant genomic information. Proportion of 
clinically relevant information delivered by variant class across 2,348 samples from the 
PCAWG pan-cancer cohort. TMB: high tumour mutational burden ≥12 mutations/Mb; MSI: 
microsatellite instability. 
 
Highlights 
 Genomic profiling requires coverage of all variant classes to unlock full utility 
 Small variants comprise just under a half of all clinically useful information 
 Appropriate analysis of copy number and structural alteration is essential 
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 Available assays are frequently suboptimal in gene and variant class selection 
 Comprehensive profiling is within the economic reach of socialised healthcare 
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